Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Inspire Medical Systems in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Inspire Medical Systems’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001609550-26-000023
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gross profit | 176,912 | 170,608 |
| Operating expenses: | ||
| Research and development | 25,826 | 27,803 |
| Selling, general and administrative | 152,204 | 144,290 |
| Total operating expenses | 178,030 | 172,093 |
| Operating (loss) | (1,118) | (1,485) |
| Interest and dividend (income), net | (3,741) | (5,066) |
| Other expense (income), net | 226 | (578) |
Item 1. Financial Statements.
FAQ
- What is Inspire Medical Systems's SG&A?
- Inspire Medical Systems (INSP) reported SG&A of $152.2M in Q1 2026.
- How has Inspire Medical Systems's SG&A changed year-over-year?
- Inspire Medical Systems's SG&A increased by 5.5% year-over-year, from $144.29M to $152.2M.
- What is the long-term trend for Inspire Medical Systems's SG&A?
- Over 4 years (2021 to 2025), Inspire Medical Systems's SG&A has grown at a 32.5% compound annual growth rate (CAGR), from $202.62M to $624.64M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Inspire Medical Systems's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude